Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.
about
A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?Smooth Muscle-Targeted Overexpression of Peroxisome Proliferator Activated Receptor-γ Disrupts Vascular Wall Structure and FunctionRole of oxidized lipids in pulmonary arterial hypertensionMetabolic Syndrome and the LungEnhanced depolarization-induced pulmonary vasoconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H oxidase 2Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of diseaseEffect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension.NADPH oxidases in vascular pathology.PPARγ attenuates hypoxia-induced hypertrophic transcriptional pathways in the heart.Electrophilic nitro-fatty acids: anti-inflammatory mediators in the vascular compartment.Puerarin Protects against Cardiac Fibrosis Associated with the Inhibition of TGF-β1/Smad2-Mediated Endothelial-to-Mesenchymal Transition.Time-dependent PPARγ Modulation of HIF-1α Signaling in Hypoxic Pulmonary Artery Smooth Muscle Cells.The Role of NOX4 and TRX2 in Angiogenesis and Their Potential Cross-Talk.Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension.Pulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B.Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway.The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferationPPAR-γ regulates carnitine homeostasis and mitochondrial function in a lamb model of increased pulmonary blood flowIs peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?Circadian clock control of Nox4 and reactive oxygen species in the vasculature.Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone.Peroxisome proliferator-activated receptor γ inhibits pulmonary hypertension targeting store-operated calcium entryEffects of chrysin (5,7-dihydroxyflavone) on vascular remodeling in hypoxia-induced pulmonary hypertension in ratsChronic hypoxia promotes pulmonary artery endothelial cell proliferation through H2O2-induced 5-lipoxygenase.Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension.PPARγ ligands regulate NADPH oxidase, eNOS, and barrier function in the lung following chronic alcohol ingestionHypoxia induces downregulation of PPAR-γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-β signaling.Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension.PPARγ Ligands Attenuate Hypoxia-Induced Proliferation in Human Pulmonary Artery Smooth Muscle Cells through Modulation of MicroRNA-21.Update on pulmonary hypertension 2009.Activation of peroxisome proliferator-activated receptor γ ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosisSerotonylated fibronectin is elevated in pulmonary hypertensionEmerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases.Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis.Enhanced caveolin-1 expression in smooth muscle cells: Possible prelude to neointima formation.Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension.Peroxisome Proliferator-Activated Receptor γ and microRNA 98 in Hypoxia-Induced Endothelin-1 Signaling.Peroxisome Proliferator-Activated Receptor γ-Mediated Inhibition on Hypoxia-Triggered Store-Operated Calcium Entry. A Caveolin-1-Dependent Mechanism.
P2860
Q27026643-426EBFB8-36EA-417A-A30D-54BCBE21441DQ27315042-8A024F6A-22D4-4890-9268-8765E54758BAQ28078566-2D06A7E4-0971-4D82-A78A-9C6E237B6124Q28384152-4E7D9301-2E39-4D52-9DF1-13FF9F74469DQ28582157-3B73BC8B-3C8E-45AD-BED3-6E85A3E6B753Q30429980-33AD4818-F369-46A5-82CD-54F9C3D63EE0Q33593476-D5C32D25-E22A-4427-A4BB-020A15FA4F6CQ33632089-37A589EE-DFAD-471F-802C-33DEBF3BF15FQ33738569-7F6103C9-2648-47DA-9608-6F080ED8EED8Q33746493-393A40ED-E404-4AA8-850A-87DE9B01CD79Q33790719-FFDA6DAE-F164-4FC6-986B-F0B4905CE11FQ33831356-56948145-9F31-400F-8016-468CBDBCED7DQ33845086-E7363FA1-E60E-461C-B2B7-0D7D523964F9Q34046462-5C8B7FCA-AA56-479F-9C18-2AE0F246E06BQ34178976-1D232A93-0E17-4082-ADF2-7817AC088EA6Q34212735-90072218-37C3-44A0-92AC-92F23ABB66F6Q34290152-92F42B3C-5965-450F-AFA8-FF096A3AE9CBQ34294854-E5AAB15C-F786-4FD9-8235-D829A7191B61Q34409704-4BD3C5C3-A2E8-4A65-A7CE-5630A769BC8CQ34897476-8A64820D-076A-40A6-AE72-088C1BE60870Q35036598-F988D931-F675-470C-892B-BFCBF9707663Q35087009-93808221-3C36-46B9-B07E-3185B8DFE95AQ35102314-01E0B5F3-D0C5-4A21-8C2B-B44AC9E68F4CQ35123675-5355D42A-002C-43AA-A88B-9DBCBB30C438Q35183085-7782436B-7C5B-4AED-B07C-FB9D539B6A9FQ35219809-D149F613-F709-42CD-8AC3-9142F0F0CB39Q35403487-F00F923D-4842-4823-8308-FBF023AD5964Q35601455-7107DBB1-9114-4EF5-8D73-8A5DA82EC0BCQ35601475-74517345-A9A1-4A1B-AB49-2D5802D8988FQ35711530-00AC1884-9A0C-4EEF-A49D-3EEEFD05E056Q35716098-E1925FBD-DC80-4CC1-9F9D-B79863BF4941Q35803453-C65006DB-A407-4A3F-9448-DE950D0AA10CQ35954579-BEABCB10-6117-4C5E-A18E-237B32F80A94Q36045577-363C7BE2-B6A8-4EA9-985A-6A10760DC312Q36063833-8E1859D2-F4BE-474A-B584-6002333C6A5DQ36093802-A056261C-2FE8-4701-9CA5-9E3C0FEBA764Q36204876-B7DA7310-BD68-400F-A185-2A379CCA304EQ36340848-B8F6A6CC-A266-4D7D-88D4-637DC1CE7AFCQ36549041-45188645-4926-4282-AFE6-AC674EEDAEEBQ36549129-5F48D42C-721D-4C47-8C9D-126AF894CDC3
P2860
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.
@en
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.
@nl
type
label
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.
@en
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.
@nl
prefLabel
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.
@en
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.
@nl
P2093
P2860
P356
P1476
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.
@en
P2093
C Michael Hart
Dean J Kleinhenz
Erik R Walp
Jennifer M Bland
Patrick O Mitchell
Rachel E Nisbet
Roy L Sutliff
P2860
P304
P356
10.1165/RCMB.2008-0132OC
P577
2009-06-11T00:00:00Z